Utilisateur:CALIBELLULE/Brouillon

OZ BIOSCIENCES

OZ Biosciences provides cutting-edge transfection and transduction reagents in order to enable life sciences researchers to achieve outstanding success. This work in scienctific research is linked to several patents and know-how for Magnetofection™, Magneto-biolisitic, magnetic-assisted transduction, Polyfection, Lipofection and 3D transfection, technologies. OZ Biosciences is currently working on UNIVAX project: A "Universal" Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines. FP-7 (HEALTH-F3-2013-601738)

HISTORY

OZ Biosciences was founded in France in 2003 by Olivier Zelphati. OZ Biosciences focused on developing innovative non-viral gene delivery technologies for gene therapy applications. OZ Biosciences researchers have published several groundbreaking achievements [1, 2]. In 2013, the american Division has been launched in San Diego, USA. In 2015, the US patent number 9,107,931 has been issued to OZ Biosciences for its new class of cationic lipids for transporting active agents into cells.

REFERENCES

1- Plank C, Zelphati O, Mykhaylyk O (2011). "Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects". Adv. Drug Deliv. Rev. 63 (14-15): 1300–31. doi:10.1016/j.addr.2011.08.002. PMID 21893135.

2- Plank C, Zelphati O, Mykhaylyk O (2011). "Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects". Adv. Drug Deliv. Rev. 63 (14-15): 1300–31. doi:10.1016/j.addr.2011.08.002. PMID 21893135.

<references> https://en.wikipedia.org/wiki/Magnetofection

EXTERNAL LINKS

www.ozbiosciences.com